Head-to-head · free

Abbott Laboratories vs BioStem Technologies, Inc.

ABT vs BSEM — return on capital, cash generation, margins and balance sheet side by side.

ABT

0 / 0

measures where ABT leads

BSEM

0 / 0

measures where BSEM leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureABT · FY2025BSEM
Revenue$44.3B—
Net income$6.5B—
Revenue growth (yearly, multi-year)0.7%—
Free cash flow$7.4B—
Free cash flow margin16.7%—
Net cash / (debt)——
ROIC9.6%—
Return on equity13.1%—
Gross margin56.4%—
Operating margin18.2%—
Net debt / EBITDA0.39x—

Figures are as reported by each company; latest fiscal year shown.

Where Abbott Laboratories's cash went (FY2025)

Capital spending
$2.2B
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full ABT profile →

Where BioStem Technologies, Inc.'s cash went

Not reported yet.

Full BSEM profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons